Periconceptional Folic Acid-Containing Multivitamin Supplementation for the Prevention of Neural Tube Defects and Cardiovascular Malformations

Foundation for the Community Control of Hereditary Diseases, Budapest, Hungary.
Annals of Nutrition and Metabolism (Impact Factor: 2.62). 11/2011; 59(1):38-40. DOI: 10.1159/000332125
Source: PubMed


The prevention of neural tube defects with periconceptional folic acid or folic acid-containing multivitamin supplementation is accepted by the scientific community; here the possible prevention of cardiovascular malformations is discussed. The aim of this presentation is to show the main findings of trials and studies that resulted in the prevention of neural tube defects and particularly cardiovascular malformations by folic acid-containing multivitamins or folic acid supplementation in order to stimulate the incorporation of folic acid-containing multivitamins or folic acid in the prevention of cardiovascular malformations.


Available from: Andrew E. Czeizel, Sep 09, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Early Nutrition Academy and the European Commission-funded EURRECA Network of Excellence jointly sponsored a scientific workshop on critical micronutrients in pregnancy, lactation, and infancy. Current knowledge and unresolved questions on the supply of vitamin D, folic acid, and iron for pregnant women, lactating women, and infants, and their health effects were discussed. The question was addressed of whether, and under which circumstances, supplementation with these micronutrients in addition to usual dietary intakes is advisable. The workshop participants concluded that public health strategies for improving supplementation with these micronutrients in pregnancy, lactation, and infancy are required. Further research priorities should focus on adequately powered human intervention trials to obtain a stronger evidence base for the amounts of vitamin D, folic acid, and iron that have optimal effects on health. The conclusions of the workshop should help to inform the scientific community as well as public health policy strategies.
    Annals of Nutrition and Metabolism 11/2011; 59(1):5-9. DOI:10.1159/000332062 · 2.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many women with psychiatric disorders want to become mothers and only a minority seek advise prior to becoming pregnant. In those women, in whom pregnancy can be planned, the decision, if a medication is required for stabilisation and which one to choose if this is the case, is easier to make than in women in whom pregnancy occurs unplanned. The physician has to weigh the risk that a relapse of the psychiatric disorder during pregnancy poses to the foetus against the reproductive risk of psychotropic drugs. This presentation is intended to assist in understanding the general principles of pharmacotherapy during pregnancy as well as the morphological, perinatal and neurobehavioural toxicity of antidepressants, antipsychotics, benzodiazepines and mood stabilisers.
    Handbook of experimental pharmacology 10/2012; 214(214):279-305. DOI:10.1007/978-3-642-30726-3_14

  • Clinical Chemistry and Laboratory Medicine 03/2013; 51(3):455-6. DOI:10.1515/cclm-2013-0004 · 2.71 Impact Factor
Show more